ABSTRACT: Soluble guanylate cyclase (sGC) is a heterodimeric heme protein and the primary nitric oxide receptor. NO binding stimulates cyclase activity, leading to regulation of cardiovascular physiology and making sGC an attractive target for drug discovery. YC-1 and related compounds stimulate sGC both independently and synergistically with NO and CO binding; however, where the compounds bind and how they work remain unknown. Using linked equilibrium binding measurements, surface plasmon resonance, and domain truncations in Manduca sexta and bovine sGC, we demonstrate that YC-1 binds near or directly to the heme-containing domain of the β subunit. In the absence of CO, YC-1 binds with a K d of 9−21 μM, depending on the construct. In the presence of CO, these values decrease to 0.6−1.1 μM. Pfizer compound 25 bound ∼10-fold weaker than YC-1 in the absence of CO, whereas compound BAY 41-2272 bound particularly tightly in the presence of CO (K d = 30−90 nM). Additionally, we found that CO binds much more weakly to heterodimeric sGC proteins (K d = 50−100 μM) than to the isolated heme domain (K d = 0.2 μM for Manduca β H-NOX/PAS). YC-1 greatly enhanced binding of CO to heterodimeric sGC, as expected (K d ∼ 1 μM). These data indicate the α subunit induces a heme pocket conformation with a lower affinity for CO and NO. YC-1 family compounds bind near the heme domain, overcoming the α subunit effect and inducing a heme pocket conformation with high affinity. We propose this high-affinity conformation is required for the full-length protein to achieve high catalytic activity.
N itric oxide (NO) regulates a phenomenal array of physiological processes, including blood pressure homeostasis, wound healing, memory formation, sexual response, and the fighting of infectious disease. 1 Impairment in NO signaling can lead to hypertension and atherosclerosis and contribute to heart attack and stroke. 2, 3 NO is produced by a class of enzymes called nitric oxide synthases (NOSs) through the oxidation of L-arginine to L-citrulline. 4, 5 The primary receptor for NO is soluble guanylyl/guanylate cyclase (sGC), a heterodimeric heme protein of ∼150 kDa that responds to binding of NO to heme through enhanced cyclase activity, producing cGMP and a signaling cascade. Treatment of cardiovascular disease by stimulating the nitric oxide pathway has long been a treatment goal, beginning more than 150 years ago with the administration of amyl nitrite 6 and nitroglycerin 7 to relieve symptoms of angina pectoris, although the mode of action of these compounds (release of NO) was not discovered until many years later. More recently, sGC, the NO receptor, has been heavily targeted for drug discovery. sGC is composed of two homologous subunits, α and β. Multiple isoforms of each subunit have been identified; however, the most common isoform is the α 1 /β 1 heterodimer (reviewed in ref 8) . Each sGC subunit consists of four domains, an N-terminal heme-nitric oxide oxygen (H-NOX) domain 9 (also called a SONO domain 10 ), a central Per-Arnt-Sim (PAS) domain, 11 a coiled-coil domain, and a C-terminal catalytic cyclase domain. 12 There is a single heme moiety in the heterodimer, associated with the β 1 H-NOX domain. The equivalent domain in the α 1 subunit has lost the ability to bind heme but appears to have retained an overall H-NOX-like fold and is therefore commonly termed the α 1 H-NOX domain. During signaling, the binding of NO to heme in the β 1 subunit leads to the formation of a pentacoordinated Fe−NO complex with proximal histidine bond breakage. 13−15 The structural change due to this event is transferred to the cyclase domain, which in turn enhances cGMP production. How this structural change is translated to increased catalytic activity is poorly understood. Moreover, elusive structural details for sGC have hampered the understanding of allosteric regulation in the protein. Structures of individual sGC domains such as the β 1 coiled-coil homodimer, 16 the α 1 PAS domain, 17 and the α 1 /β 1 heterodimeric cyclase domain 18 have recently been determined. Insight into the H-NOX and PAS domains comes from the structures of prokaryotic homologous proteins, 10,19−21 yet an understanding of how these domains are arranged in the functional NO sensor remains unknown.
Small molecule stimulators of sGC have been discovered, opening new doors for drug discovery in the treatment of cardiovascular diseases. 22 The first of these is compound YC-1, a benzylindazole derivative that inhibits platelet activation through stimulating sGC. 23 YC-1 stimulates sGC 2−4-fold in the absence of NO but acts synergistically with CO or NO to achieve several hundred-fold activation. 24, 25 Binding of YC-1 can also overcome the inhibitory phosphorylation of sGC. 26 Compound BAY 63-2521 (riociguat), a YC-1 derivative, has just completed phase III clinical trials 27−30 and has been approved by the Food and Drug Administration for treatment of pulmonary hypertension (as Adempas). These compounds stimulate sGC activity in an NO-independent and hemedependent manner, but how they bind to sGC and how they stimulate catalytic activity are unknown. Studies aimed at determining the binding site for YC-1 family compounds have suggested the pseudosymmetric site in the cyclase domain, 31, 32 the α 1 H-NOX domain, 33, 34 and the β 1 H-NOX domain. 35−38 A second class of compounds that function through replacing the sGC heme, which can be lost upon oxidation, have also been developed. 22 Prominent among these are compounds BAY 58-2667 (cinaciguat) 39 and HMR1766 (ataciguat). 40 We developed sGC from the tobacco hornworm/hawkmoth (Manduca sexta) for biophysical and biochemical characterization and to help with uncovering the mechanism underlying YC-1 stimulation. 33 ,41−43 M. sexta sGC (Ms sGC) is highly homologous to its mammalian counterparts and responds well to YC-1 family compounds. Expression of N-terminal heterodimeric constructs lacking the α 1 /β 1 cyclase domains (Ms sGC-NT constructs) leads to proteins that preserve YC-1 binding. Binding of YC-1 to Ms sGC leads to enhanced CO and NO binding 33 and to the trapping of CO in the heme pocket after laser photolysis, leading to rebinding with heme before escape from the protein (geminate recombination). 41 Ms sGC-NT is an elongated molecule with a central parallel coiled-coil domain, based on chemical cross-linking, mass spectrometry, and small-angle X-ray scattering (SAXS) studies. 43 In this model, the coiled-coil domain acts as an organizing center for the PAS, H-NOX, and, presumably, cyclase domains. Here, we demonstrate that the α subunit serves to keep the β subunit heme domain in a conformation with reduced affinity for CO and that YC-1 binds directly to the β subunit, inducing a highaffinity heme domain conformation.
■ EXPERIMENTAL PROCEDURES
Materials. All chemicals were obtained from Sigma-Aldrich, restriction enzymes from Fermentas, and purification columns from GE Healthcare unless otherwise indicated. Pfizer compound 25 targeted to sGC (PF-25) was kindly provided by L. Roberts of Pfizer Inc. 44 DEA/NO was kindly provided by K. Miranda (The University of Arizona).
sGC Protein Expression Vectors. Construct Ms sGC CT1 (α 1 residues 272−699 and β 1 residues 199−600) was obtained by polymerase chain reaction (PCR) amplification from a fulllength Ms sGC pETDuet1 construct. 33 Forward primer 5′-ggatccgaccaaagtgacagattt-3′ and reverse primer 5′-gcggccgcctaagttggttcttct-3′ were used for the α 1 subunit, and the PCR product was cloned into the pETDuet1 vector using the BamHI and NotI restriction sites. Similarly, the Ms sGC CT1 β 1 fragment was obtained by PCR amplification from the Ms sGC full-length pETDuet1 construct using primers 5′-catatgacgttgtctcttgaacca-3′ and 5′-gatatcttaatggatcttcctggt-3′, and the PCR product was cloned into the same pETDuet1 vector using the NdeI and EcoRV restriction sites. The final construct had a His 6 purification tag fused to the N-terminus of the α 1 subunit. Stop codons were inserted at α 1 Asn 451 and β 1 Thr 381 using the QuikChange lightning site-directed mutagenesis kit (Stratagene, La Jolla, CA), leading to constructs containing just the PAS and coiled-coil domains (α 1 residues 272−450 and β 1 residues 199−380). Possible boundaries for stable PAS domain expression were surveyed using the Ms sGC α 1 PAS-CC-cyclase (residues 272− 699) and β 1 PAS-CC-cyclase (residues 199−600) cloned into a single plasmid (pETDuet-1, Novagen) or cloned individually into the pETDuet-1 (α 1 ) or pET28a+ (β 1 ) plasmid. Domain boundaries were examined through introduction of stop codons, using the QuikChange mutagenesis kit. The Ms sGC β 1 PAS construct (residues 199−319) in pET28a+ was obtained by inserting a stop codon at position 320. The Ms sGC α 1 PAS domain, spanning residues 279−425, was cloned into the pETHSUL vector, kindly provided by the Loll laboratory. 45 A ligation-independent cloning (LIC) approach was undertaken as described previously, 45 using forward primer 5′-agattggtggcatcggcgtggctagcttctgc-3′ and reverse primer 5′-gaggagagtttagacttaaccatcctgagccctagcc-3′ (LIC overhang residues are underlined). The vector was made ready for ligation using the direct digestion method with BseRI (New England Biolabs). A stop codon was introduced at position 405 to yield wild-type construct Ms sGC-P25α, spanning residues 279−404. A triple cysteine-to-alanine mutant (C285A/C352A/C374A, Ms sGC-P35α) was produced to assist in crystallization. 17 All mutations were introduced using the QuikChange lightning site-directed mutagenesis kit. Vector pSUPER, containing a dual-tagged catalytic domain of SUMO hydrolase (dtUD1) fused to the N-terminus of SUMO, was also kindly provided by the Loll laboratory. 45 Ms sGC β 1 (1−380), containing the H-NOX and PAS domains and most of the CC domain, was amplified by PCR and subcloned into the pGEM-T vector. The fragment was then cut with the restriction enzymes NcoI and NotI and inserted into the pET28c vector, yielding a Cterminal His 6 tag.
A single-step insertion methodology 46 was used for insertion of the BirA recognition sequence (Avi-tag, GLNDIFEAQKIE-WHE) at the C-terminus of the Ms sGC-NT21 β 1 subunit (residue 380, ref 43) and Ms sGC β 1 (1−380) using forward primers 5′-ggaattggaaaaacagaagggtggcggtctgaacgacatcttcgaggctcaaaaaatagagtggcacgagtaggacaggcttctttactcagtg-3′ and 5′-ggaattggaaaaacagaagggtggcggtctgaacgacatcttcgaggctcaaaaaatagagtggcacgaggcggccgcactcgagcaccaccac-3′ and common reverse primer 5′-cttctgtttttccaattccagctctcggaatgtttgttgaag-3′. The Avi tags with two N-terminal glycine linker residues are underlined. Similarly, a C-terminal Avi tag was added to α 1 PAS domain construct Ms sGC-P25α using forward primer 5′-gactcttcatatccgatataggtggcggtctgaacgacatcttcgaggctcaaaaaatagagtggcacgagtgacttcatgatgcgacgagag-3′ and reverse primer 5′-tatatcggatatgaagagtccccttccagtcagaccttcgag-3′. Escherichia coli biotin protein ligase BirA in vector pGEX-4T-1, with an N-terminal GST tag linked to a thrombin cleavage site and a C-terminal His 6 tag, was kindly provided by M. Kuhns (The University of Arizona). The thrombin cleavage site was changed to a TEV cleavage site using forward primer 5′-ccatcctccaaaatcgggcgaaaacttgtatttccagggatccaaggataacaccg-3′ and reverse primer 5′-cggtgttatccttggatccctggaaatacaagttttcgcccgattttggaggatgg-3′ (TEV cleavage site underlined). Additionally, a stop codon was inserted in front of the His 6 tag.
Expression and Purification of Ms sGC PAS Domains. Ms sGC α 1 PAS with an N-terminal His-tagged SUMO fusion was expressed in E. coli strain BL21(DE3) pLysS. Cells were grown at 37°C to an OD 600 of 0.6 before being induced with 0.5 mM isopropyl 1-thio-β-D-thiogalactopyranoside (IPTG) and then grown at 20°C; cells were harvested after 16 h. Purification steps were performed at 4°C. Cell pellets were resuspended in lysis buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, 20 mM imidazole, 0.1 mg/mL DNase I, 2 mM MgCl 2 , 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM benzamidine, and 1 μg/mL aprotinin, leupeptin, and pepstatin], disrupted using a French press cell (1000 psi), clarified by ultracentrifugation (45Ti rotor, 40000 rpm for 30 min), supplemented with 10% glycerol (w/v) and 5 mM β-mercaptoethanol, and loaded onto a 5 mL Ni-NTA column previously equilibrated with binding buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, 20 mM imidazole, and 5 mM β-mercaptoethanol]. The column was washed with binding buffer until the baseline was reached, and bound protein was eluted using an imidazole gradient ranging from 20 to 300 mM over 100 mL (20 bed volumes) by mixing binding buffer and elution buffer (binding buffer supplemented with 500 mM imidazole). Cleavage of the N-terminal His-tagged SUMO domain was achieved by adding 1 mg of purified SUMO hydrolase (dtUD1) to the pooled PAS-containing fractions followed by overnight dialysis at 4°C against two changes of dialysis buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, 5% glycerol (w/v), and 10 mM β-mercaptoethanol]. The dialyzed product was again loaded onto the Ni-NTA column to remove the His-tagged SUMO and SUMO hydrolase proteins, followed by concentration to ∼3 mL and further purification over an S-200 size exclusion column previously equilibrated with equilibration buffer [50 mM Tris-HCl (pH 7.4), 200 mM NaCl, 5% glycerol (w/v), and 5 mM dithiothreitol]. The final material was concentrated to 10−15 mg/mL using a Vivaspin concentrator (Sartorius Stedim Biotech) and stored at −80°C. A final yield of 2−3 mg of highly pure protein was obtained per liter of cell culture.
Ms sGC β 1 PAS was expressed in E. coli strain Rosetta pLysS. Cells were grown at 37°C to an OD 600 of 1.0 and induced with 0.2 mM IPTG, after which they were grown while being slowly shaken (90 rpm) at 18°C for 18 h before being harvested. The cell lysate was obtained as described for the α 1 PAS domain, and the protein was purified using Ni-NTA followed by S-200 size exclusion chromatography. A yield of 30−40 mg was obtained per liter of cell culture.
SUMO hydrolase (dtUD1) was expressed in strain BL21-(DE3) pLysS. Cells were grown at 37°C until the OD 600 reached 0.6, induced with 0.5 mM IPTG, and grown at 30°C for 6 h before being harvested. Purification was performed using Ni-NTA column chromatography as described previously. 45 BirA was expressed in strain BL21(DE3) pLysS. Cells were grown at 37°C to an OD 600 of 1.0, and expression was induced with 0.5 mM IPTG, followed by growth at 16°C for 20 h before being harvested. Cells were lysed by sonication at 4°C in lysis buffer and clarified by ultracentrifugation, and the supernatant was loaded onto a GSTrap FF column previously equilibrated with 50 mM sodium phosphate buffer (pH 7.4) containing 300 mM NaCl. Bound GST-tagged BirA was eluted with the buffer described above supplemented with 20 mM glutathione. Fractions were incubated for 24 h with 5 μM His 6 -tagged TEV protease, and the mixture was loaded onto a GSTrap FF column in tandem with a Ni-NTA column. The flow through was collected and the protein concentrated and stored at −80°C.
TEV protease with N-terminal polyhistidine, C-terminal polyarginine, and mutation S219V was prepared from a previously described pRK793 vector. 47 TEV protease was expressed in E. coli strain BL21(DE3) pLysS. Cells were grown to an OD 600 of 0.6 at 37°C, induced with 1 mM IPTG, and grown at 30°C for 6 h before being harvested. Cell pellets were resuspended in binding buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, and 20 mM imidazole], disrupted using a French press cell (1000 psi), and clarified by ultracentrifugation (45Ti rotor, 40000 rpm for 30 min). The supernatant was supplemented with 10% glycerol (w/v) and 5 mM β-mercaptoethanol before being loaded onto a 5 mL Ni-NTA column previously equilibrated with binding buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, 20 mM imidazole, and 5 mM β-mercaptoethanol]. The column was washed with binding buffer until the baseline was reached, and bound protein was eluted using an imidazole gradient ranging from 20 to 300 mM over 100 mL (20 bed volumes) by mixing binding buffer and elution buffer (binding buffer supplemented with 500 mM imidazole). Fractions containing TEV protease were pooled, buffer exchanged with final storage buffer [50 mM sodium phosphate (pH 7.4), 300 mM NaCl, 25% glycerol, 1 mM EDTA, and 1 mM DTT], concentrated to a final concentration of ∼4 mg/mL, and frozen at −80°C.
Expression and Purification of Heme-Containing Manduca and Bovine sGC Proteins. Ms sGC-NT13, Ms sGC-NT19, and Ms sGC-NT21 were expressed in E. coli and purified using Ni-NTA, StrepTactin (Ms sGC-NT19), and size exclusion chromatography, as previously described. 33, 43 Ms sGC β 1 (1−380) was expressed in E. coli strain Rosetta pLysS. Cells were grown at 37°C to an OD 600 of 1.0 and cooled on ice before being induced. The culture was induced with 0.5 mM IPTG, supplemented with 25 μM δ-aminolevulinic acid, and grown at 30°C for 6 h before being harvested. Cell pellets were resuspended in lysis buffer B [50 mM Tris-HCl (pH 8.5), 10 mM NaCl, 0.1 mg/mL DNase I, 2 mM MgCl 2 , 1 mM PMSF, 1 mM benzamidine, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, and 1 mM dithionite], disrupted with a French pressure cell, and clarified by ultracentrifugation. The supernatant was supplemented with 10% (w/v) glycerol, 5 mM β-mercaptoethanol, and an ∼100-fold excess of dithionite (∼1 mM, assuming 2 mg of protein/L of cell culture). The sample was loaded onto a DEAE anion exchange column or Q-FF Sepharose column previously equilibrated with buffer A [20 mM Tris-HCl (pH 8.5), 1 mM EDTA, and 5 mM β-mercaptoethanol], the column washed with buffer A, and protein eluted with a 0 to 300 mM NaCl elution gradient (200 mL) using buffer A (0 mM NaCl) and buffer B (buffer A with 500 mM NaCl). Colored fractions were pooled and loaded onto the Ni-NTA column and eluted with 30 mM EDTA in a single-step elution. Fractions were supplemented with fresh dithionite and tris(2-carboxyethyl)phosphine (TCEP), concentrated, and further purified by being run through a size exclusion S200 column previously equilibrated with gel filtration buffer [50 mM potassium phosphate buffer (pH 7.4), 100 mM KCl, 2 mM EDTA, 5% glycerol, and 1 mM TCEP], where it ran as a monomer. The purified protein was supplemented with dithionite, concentrated to 5−10 mg/mL, and stored at −80°C.
For the bovine sGC β 1 H-NOX and β 1 H-NOX-PAS, we used a systematic site-directed mutagenesis approach to determine the appropriate C-terminal ends for optimal expression and solubility of the proteins (J. Hines, L. Rassouli-Taylor, J. Burstyn, and E. Garcin, Raman studies of bovine soluble guanylate cyclase, manuscript in preparation). We used the untagged β 1 (1−385) (residues 1−385) construct cloned into the pET30b plasmid (kind gift of J. Burstyn) and introduced stop codons at various positions using the QuikChange mutagenesis kit. Bt sGC β 1 H-NOX (residues 1−197) and sGC β 1 H-NOX-PAS (residues 1−359) in pET30b were obtained by inserting a stop codon at positions 198 and 360, respectively. These constructs displayed the highest levels of expression and solubility in E. coli cells. Purification of both constructs was performed as follows. Each construct was expressed in E. coli strain BL21(DE3) pRIPL. Cells were grown at 37°C to an OD 600 of 1.0 and cooled on ice before being induced. The culture was induced with 0.4 mM IPTG, supplemented with 450 μM δ-aminolevulinic acid and ferric citrate, and grown at 20°C for 24 h before being harvested. Cell pellets were resuspended in lysis buffer [20 mM Tris-HCl (pH 7.5), 50 mM NaCl, DTT, 0.5 mg/mL lysozyme, 300 units of benzonase (SIGMA), and one tablet of EDTA-free protease inhibitor cocktail tablet/50 mL (Roche)], disrupted by sonication, and clarified by ultracentrifugation. We used 10 mM DTT to keep the β 1 H-NOX protein reduced and 1 mM DTT for the β 1 H-NOX-PAS construct. The clarified lysate was loaded onto a Q-FF Sepharose column previously equilibrated with buffer A [20 mM Tris-HCl (pH 7.5), 50 mM NaCl, and DTT], and the protein was eluted with a 0.05 to 1 M NaCl elution gradient (buffer B being buffer A with 1 M NaCl). Colored fractions were pooled, dialyzed into buffer A, and loaded onto an S75 size exclusion column equilibrated in buffer A. Colored fractions were pooled and loaded onto a second QFF column pre-equilibrated in buffer C [20 mM Tris-HCl (pH 8.5), 50 mM NaCl, and TCEP]. The protein was eluted with a 0.05 to 1 M NaCl gradient (buffer D being buffer C with 1 M NaCl). The colored fractions were pooled and dialyzed into buffer C (10 and 1 mM TCEP for β 1 H-NOX and β 1 H-NOX-PAS, respectively). The purified protein was concentrated to ∼10 mg/mL and stored at −80°C.
Determination of Dissociation Constants for CO. CO dissociation constants were measured by titrating CO from a saturated solution into sGC protein and monitoring the appearance of the CO-bound Soret absorption band, as described previously. 33, 43 The Ms sGC β 1 (1−380) and Bt sGC β 1 (1−197) samples were prepared in Ar-purged buffer supplemented with excess dithionite. CO binding experiments were performed in a 10 cm path length cuvette for Ms sGC-β 1 (1−380) and Ms sGC-NT21 using a Cary 50 spectrophotometer (Varian) with a modified sample holder. Binding data in the presence and absence of 50 μM YC-1 were plotted using a single-site saturation ligand binding model in SigmaPlot (SPSS, Inc., Chicago, IL).
To extract linked equilibrium binding behavior, CO binding assays were performed for Ms sGC-NT21 (10 cm cuvette) and Ms sGC-NT13 (1 cm cuvette) at various YC-1 concentrations.
The stimulation of CO binding in the presence of YC-1 was described with a cooperative two-site model with four states: free protein, protein bound to CO only, protein bound to YC-1 only, and protein bound to both CO and YC-1. Independent binding of CO and independent binding of YC-1 are described with association constants K a CO and K a YC-1 , respectively, with an assumed cooperativity constant K int representing coupling between the two binding processes. This model is described with a binding polynomial of the form
in which each term represents the statistical weight for one of the four states. The fraction of CO sites occupied is given by the ratio of the weights for states with CO bound to all four states:
Estimates for the model parameters K a CO , K a YC-1 , and K int were obtained from a global fit of θ to the normalized absorbance changes at wavelengths of 423 and 433 nm, using MATLAB (The MathWorks, Inc., Natick, MA). The product K a YC-1 K int indicates the association constant for binding of YC-1 to the CO-bound complex, so its inverse represents the dissociation
To directly measure the binding of YC-1 family compounds to Ms sGC-NT-CO, an ∼2 nm shift in the Soret band maxima was monitored as a function of compound concentration. The compound was titrated into a 1 or 10 cm cuvette containing a CO-saturated protein solution. The K d for ligand binding in the presence of CO was calculated by plotting the Soret shift difference with respect to the increasing concentrations of the ligand and fitting to a single-site saturation ligand binding model in SigmaPlot.
Fluorescence Anisotropy. Fluorescence anisotropy was measured using a JASCO J-815 CD fluorescence spectrometer equipped with an anisotropy attachment (JASCO). Average anisotropy was measured at 20°C for 60 s using an excitation wavelength of 325 nm. Anisotropy was calculated using total fluorescence above 380 nm, which was measured 90°incident to the excitation beam. Initial anisotropy was measured for a 2 μM YC-1 solution in 10 mM Tris-HCl (pH 7.5) by titrating Ms sGC α 1 P25α or β 1 PAS or lysozyme, and the sample was mixed thoroughly for 30 s before anisotropy measurements were taken. Data were fit using a one-site total binding model implemented in GraphPad (GraphPad Software, Inc.).
Surface Plasmon Resonance Binding Experiments. In vitro biotinylation of Avi-tagged Ms sGC-NT21, Ms sGC α 1 PAS, and Ms sGC β 1 (1−380) was performed using E. coli BirA biotin ligase. A reaction mixture containing 30−40 μM Avitagged protein, 1−2 μM purified BirA, 0.5 mM biotin, 10 mM magnesium acetate, and 10 mM ATP was incubated at 4°C for 6 h and loaded onto a Ni-NTA column (Ms sGC-NT21) or Superdex-75 analytical gel filtration column [Ms sGC α 1 PAS and Ms sGC β 1 (1−380)] to remove excess reaction components. Biotinylation was confirmed by a monoclonal anti-biotin antibody (Sigma-Aldrich) Western blot. All SPR studies were performed on a Biacore T100 instrument at 20°C. Both reference and sample CM5 sensor chip surfaces (GE Healthcare) were prepared by an amine coupling methodology following the procedures in the Biacore T100 instrument manual. The chip surfaces were first activated by using a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC). NeutrAvidin (Pierce), 100 μg/mL in 10 mM NaOAc (pH 4.5), was then immobilized to 10000 response units by passing it over the activated surfaces. Running buffer consisted of 10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 0.05% Tween 20. Any remaining active esters were blocked with ethanolamine, and the immobilized NeutrAvidin chip surface was washed three times with a 30 s pulse of 10 mM HCl. Biotinylated Ms sGC proteins were captured onto the NeutrAvidin-coated chip surfaces by injecting 25 μM protein at a flow rate of 10 μL/min until ∼10000 response units had been achieved. Running buffer consisted of 50 mM potassium phosphate buffer (pH 7.4), 100 mM KCl, 2 mM EDTA, and 1 mM TCEP. The surfaces were washed with running buffer for 2 h at a flow rate of 100 μL/min until a stable response was obtained, indicating no further dissociation of the biotinylated proteins. Each chip has four flow cells allowing simultaneous measurements on one reference and three active surfaces. The Biacore T100 MIX function was used to mix DEA/NO or NaOH alone (0.5 mM DEA/NO stock in 10 mM NaOH and 1% DMSO, contained in an Ar-purged sealed Biacore vial) with varied concentrations of PF-25 in 50 mM potassium phosphate buffer (pH 7.4), 100 mM KCl, 2 mM EDTA, and 1 mM TCEP containing 1% DMSO to achieve a final DEA/NO concentration of 25 μM. Various concentrations of PF-25 containing DEA/NO or NaOH were injected over the surface at a rate of 25 μL/min with 115 s association and 240 s dissociation times. Running buffer consisted of 50 mM potassium phosphate buffer (pH 7.4), 100 mM KCl, 2 mM EDTA, 1 mM TCEP, and 1% DMSO. Solvent correction curves were used to compensate for any mismatch between the sample buffer and the running buffer. Data were analyzed with Biacore T100 evaluation software to obtain the offset corrected response [R, measured in response units (RU)] and the expected maximal response (R max ) based on the response from the immobilized protein (R immob ) and the relative molecular weights of ligand and analyte: For measurements in cases in which binding was very weak (−NO), the dissociation constant was obtained from a singlesite saturation ligand binding model with R max constrained, while for tighter binding (+NO), R max was allowed to be fit. Fitting was conducted with SigmaPlot:
■ RESULTS
The sGC α Chain Inhibits CO Capture by Heme in the β Chain. To begin to understand how the affinity of NO and CO for sGC heme is modulated, we examined binding of CO to a variety of sGC proteins lacking specific domains but retaining heme. Measurements were taken in the presence or absence of YC-1 or related compounds. We focused on CO binding because its affinity for ferrous heme was lower than that of NO, allowing for the measurement of equilibrium dissociation constants, and because of its clear response to YC-1 binding. Measurements were taken with Ms sGC-NT constructs (Figure 1 ), taking advantage of their high stability and high yields from bacterial expression. 33,41−43 Ms sGC-NT constructs are heterodimeric proteins lacking the C-terminal cyclase domains while retaining YC-1 binding. We previously demonstrated that YC-1 binding leads to tighter CO and NO binding and to a geminate recombination phase upon CO photolysis. 33, 41 Here, we extend these studies to include proteins completely lacking the α 1 chain and, where needed, using a cuvette with a path length of 10 cm, allowing for more precise measurement of the tighter binding constants that occur in the presence of YC-1 ( Figure 2 and Table 1 ).
The Ms sGC coiled-coil domain likely ends at α 1 Pro 460 and β 1 Pro 390. 16, 42, 43 We trimmed the C-terminal end of Ms sGC-NT2 by 21 residues to remove a portion of the linker between the coiled-coil and cyclase domains, as well as a small portion of the coiled-coil domain, yielding Ms sGC-NT13 and Ms sGC-NT19, which are identical except for addition of a Strep purification tag to Ms sGC-NT19. Both proteins display a small increase in CO binding affinity in the absence of YC-1, but no significant change in CO affinity in the presence of YC-1 (Table 1) (Table 1) ]. These measurements were taken in a 10 cm cuvette, allowing protein concentrations as low as 50 nM to be used and minimizing the depletion of free CO through heme binding. Thus, Ms sGC-NT21 binds CO 20−40-fold tighter than Ms sGC proteins containing the α 1 H-NOX domain and still responds to YC-1, displaying a 10-fold increase in CO binding affinity when YC-1 is present. These data are consistent with previous studies indicating YC-1 family compounds stimulate NO-dependent catalysis in sGC proteins lacking the first 259 residues of α 1 .
48−50 To further narrow the YC-1 binding location, we examined an Ms sGC protein lacking the entire α 1 chain. This protein binds CO with high affinity (∼0.2 μM) in the presence or absence of YC-1 ( Figure 2 and Table 1 ). Thus, YC-1 appears to have no effect on CO binding affinity in the absence of the α chain, and importantly, CO binding is as tight in the absence of the α chain as it is in the presence of YC-1 for any of the heterodimeric Ms sGC proteins, displaying a K d CO value of ∼200 nM. We conclude that both the α 1 PAS and H-NOX domains lower the CO affinity for the sGC heme. Binding of YC-1 appears to relieve this restraint.
We examined the bovine β 1 subunit to extend our results to a mammalian sGC. The bovine protein displays the same overall domain structure as Ms sGC and has an overall level of sequence identity of 60% with the β 1 subunit and 39% with the α 1 subunit. We produced two Bt sGC forms, one containing just the H-NOX domain and one containing the H-NOX and PAS domain. As with Ms sGC β 1 , neither Bt sGC β 1 construct displayed YC-1 sensitivity (Table 1) . Binding of CO to the bovine protein was less tight, however, and differed between the H-NOX domain-and H-NOX-PAS domain-containing proteins, with the shorter construct having the greatest affinity (∼1 μM) and the longer construct binding with ∼10-fold less affinity. Homodimer formation in Bt sGC β 1 (1−359) may contribute to the lower CO affinity [Ms sGC β 1 (1−380) behaves as a monomer].
Binding Affinity of YC-1 for Ms sGC. The data in Table 1 indicate the YC-1 binding site is within the Ms sGC-NT21 construct and, furthermore, that YC-1 enhancement of CO binding requires an intact α 1 PAS domain. Measurement of the binding affinity of YC-1 for sGC, which is needed to clarify where on the protein binding takes place, is frustrated by the poor solubility of YC-1 in aqueous solutions and by the tendency for YC-1 to bind nonspecifically to proteins. We therefore employed a multidimensional binding assay to extract the YC-1 dissociation constant through analysis of the linked equilibria between CO binding and YC-1 binding ( Figure 3 and Table 2 ). For a system displaying linked equilibria, binding of either ligand, in this case CO or YC-1, will affect the binding of the other. We therefore measured CO binding affinity as a function of YC-1 concentration for Ms sGC-NT21 (10 cm cuvette) and Ms sGC-NT13 (1 cm cuvette). Linked equilibrium analyses yielded K d YC-1 values of 9.3 and 21 μM, respectively, for the two proteins in the absence of NO and CO (Table 2 ). Cooperativity factors of 14 and 19 (Table 3) , reflecting the influence of one ligand on binding of the other, were also derived from these data, from which the dissociation constant for the binding of YC-1 to the CO-saturated protein (K d YC-1 ′) can be derived. These values were 0.7 and 1.1 μM for Ms sGC-NT21 and Ms sGC-NT13, respectively (Table 2) .
We also directly measured binding of YC-1 to CO-saturated heterodimeric Ms sGC proteins by monitoring the ∼2 nm blue shift in the Soret absorption band that occurs upon YC-1 binding. 41, 51 Monitoring of this shift while titrating in YC-1 allowed the estimation of compound affinity (Figure 4 , Table b Measured in a 10 cm cuvette, using 0.1 μM protein.
c Measured in a 1 cm cuvette, using 0.5 μM protein. Titrations were performed in a 10 cm cuvette at room temperature with 0.1 μM protein in buffer containing 50 mM potassium phosphate (pH 7.4), 100 mM KCl, 5% glycerol, and YC-1 concentrations ranging from 0 to 50 μM. Table 3 . b Estimated assuming linked equilibria:
c From SPR (see the text). Values in the absence of NO were fit with a calculated R max , and those in the presence of NO were fit with a floating R max . Errors are from the fitting. NB means no binding.
d From fitting of the Soret shift (1 cm cuvette). Values are means and the standard deviation of three to five independent measurements. For YC-1, 1 μM protein was used. For PF-25, both 1 and 0.5 μM protein was used. 2). We examined binding of YC-1 to Ms sGC-NT21-CO and Ms sGC-NT13-CO in 10 and 1 cm cuvettes, respectively, which yielded values nearly identical to those obtained from the linked equilibrium analysis (Table 2) . Likewise, estimating cooperativity factors by linked equilibrium analysis or by the ratio of
′ yielded similar values (Table 3) , indicating good internal consistency between the two approaches. A shift in Soret band maxima was not observed for Ms sGC β 1 (1−380).
Relative YC-1, BAY 41-2272, and PF-25 Binding Affinities. We examined binding by compounds BAY 41-2272, which is active at concentrations lower than those of YC-1, 22 and Pfizer compound 25 (PF-25), a recently described compound with greater aqueous solubility. 44 PF-25 behaves like other YC-1 family compounds, stimulating human sGC in the presence of NO (EC 20 = 80 nM) and relaxing preconstricted aortic rings (IC 50 = 60 nM). Both compounds are derived from YC-1 (Figure 1) , differing mainly through substitution of the YC-1 furan ring. Affinity measurements were taken using linked equilibria and/or the Soret band shift. Interestingly, differences were observed among the compounds for binding to both the unliganded and CO-liganded proteins, and for their associated cooperativity factors. As with CO, YC-1 family compounds also bind tighter to Ms sGC-NT21 than to Ms sGC-NT13, indicating that the α 1 H-NOX domain not only interferes with CO binding but also interferes with YC-1 family compound binding ( Table 2) . The effect of H-NOX removal on stimulator binding is greater for BAY 41-2272 (∼9-fold) than for YC-1 or PF-25 (∼2-fold).
Binding of stimulator compounds to the CO complexes is much tighter than binding to the unliganded proteins. The greatest enhancement is seen for BAY 41-2272, which binds to the CO complex with a K d of 30−90 nM, whereas YC-1 binds with a K d of ∼1 μM and PF-25 with a K d of ∼3 μM ( Table 2) . PF-25 binds particularly poorly to the unliganded proteins (70−150 μM).
Measuring PF-25 Binding Using Surface Plasmon Resonance. We hypothesized that YC-1 family compounds bind to the α 1 PAS domain because (i) PAS domains commonly bind small molecules in their capacity as signaling proteins, 11 (ii) the α 1 PAS domain is required for observing a YC-1-dependent enhancement in CO affinity (Table 1) , and (iii) addition of YC-1 did not lead to a shift in the Soret absorption band for any of the proteins lacking the α chain. To directly address whether YC-1 binds to the α 1 PAS domain, we used surface plasmon resonance (SPR), allowing for binding measurements that were not dependent on heme spectra. To accomplish this, we specifically biotinylated Ms sGC NT21, α 1 PAS, and β 1 (1−380) at their C-termini, using biotin ligase (BirA) and sGC proteins modified to contain the BirA recognition sequence. 52 The biotinylated proteins were captured in the SPR instrument on a NeutrAvidin-coated sensor chip, and analyte binding was examined. Unfortunately, neither YC-1 nor BAY 41-2272 was suitable for SPR binding measurements because of their poor solubility in aqueous buffer. Introducing these compounds required a percentage of DMSO greater than the percentage that was well tolerated by the protein over the course of the measurements, which take hours to complete. We therefore turned to PF-25, a compound better suited to SPR measurements because of its greater aqueous solubility.
Binding of PF-25 to Ms sGC NT21 was clearly observed in the SPR instrument ( Figure 5) . Binding was rapid, as expected from our CO titration experiments, making k on measurements unreliable. Release was also rapid and difficult to quantify. Ligand affinity was therefore estimated through saturation binding, leading to a K d PF-25 of 153 μM, a value similar to that observed through analysis by linked equilibria. Unexpectedly, binding to Ms sGC β 1 (1−380) was also observed (K d PF-25 = 92 μM). In contrast, binding to Ms sGC α 1 PAS was not observed. Thus, these data indicated PF-25 binds to the β 1 chain between residues 1 and 380.
Measuring binding of PF-25 to the CO-saturated protein was not possible because the SPR instrument has an in-line degasser to prevent bubble formation. We therefore examined binding after addition of NO to the heme-containing constructs, which could be saturated with small amounts of NO released in situ. Unlike with CO, only nanomolar concentrations of NO were Could not be readily measured by global fitting because of the large cooperativity factor, requiring that both 1 and 10 cm cuvettes be used. required for these measurements because of the high affinity of NO for sGC heme (picomolar to nanomolar) and the small amount of protein captured on the chip surface (picomoles). Binding of NO to heme enhanced binding of PF-25 to Ms sGC NT21 as expected (K d PF-25 ′ = 11 μM) but, in contrast to CO, also enhanced binding of PF-25 to Ms sGC β 1 (1−380) ( Figure  5 and Table 2 ), yielding a K d PF-25 ′ of 7 μM. Surprisingly, PF-25 also bound slightly weaker to Ms sGC-NT21-NO than to Ms sGC-NT21-CO. The reason for these differences in binding is not yet clear but is presumably due to differences in the conformations of the NO and CO complexes.
Binding of YC-1 to Ms sGC PAS Domains Is Not Observed by Fluorescence Anisotropy. We examined binding of YC-1 to PAS domains in solution using fluorescence anisotropy. Various proteins were titrated into a YC-1-containing solution, and changes in YC-1-dependent fluorescence anisotropy were monitored. Weak binding (>100 μM) was indicated for Ms sGC α 1 PAS, but not for lysozyme. However, the data were extremely noisy, nonsaturable, and slow to equilibrate, suggesting the observed interaction was nonspecific. Likewise, a weak signal was also seen for the β 1 PAS domain, although it was less substantial, and also likely to be due to nonspecificity. Binding to heme-containing Ms sGC proteins could not be measured because of signal quenching by the heme. Although inconclusive, these data indicate the individual sGC PAS domains do not contain the YC-1 binding site, consistent with our SPR data.
■ DISCUSSION
YC-1 family compounds show great promise for the treatment of cardiovascular disease through their stimulation of sGC, yet their mechanism of action remains unknown. Likewise, the mechanism by which binding of NO to sGC heme stimulates cyclase activity is unclear. Here, we show that (i) the α 1 PAS domain inhibits binding of CO, and presumably NO, to the β 1 heme domain, (ii) binding of YC-1 overcomes this inhibition, (iii) binding of YC-1 and CO or NO to heterodimeric sGC displays linked equilibria, with binding of one enhancing binding of the other, (iv) monomeric β 1 sGC displays high CO affinity and loss of CO−YC-1 linked equilibria, and (v) YC-1 binds to the β 1 chain, most likely in the heme domain. A model emerges from our study in which the α 1 H-NOX and PAS domains act to inhibit the β 1 H-NOX domain, which, in turn, acts to inhibit the cyclase domain. Activation of cyclase can occur through the relieving of either inhibitory contact; maximal activity occurs when both inhibitory contacts are removed. In what follows, we expand upon these findings.
YC-1 Binding to or near the sGC Heme Domain. Discovery of the YC-1 binding site has been challenging because of the difficulty in working with sGC protein.
Suggestions in the literature for where YC-1 binds invoke nearly all sGC domains, including the α 1 H-NOX domain, 33, 34, 53 the catalytic domain, 31, 32, 54 and the heme domain. [35] [36] [37] [38] 55, 56 Here, using SPR, we demonstrate that binding is to the N-terminal portion of the β 1 chain. Because binding to the β 1 PAS domain could not be detected by fluorescence anisotropy measurements, binding is most likely to the heme-containing β 1 H-NOX domain. Additionally, a recent report notes that a human sGC construct lacking both H-NOX domains is not stimulated by BAY 41-2272, while full-length sGC is. 57 Binding of YC-1 leads to an ∼2 nm shift in the Soret absorption band for the CO complex, 38, 41, 55 which we used to determine the YC-1 dissociation constants to be 0.8 and 0.6 μM for Ms sGC-NT13-CO and Ms sGC NT21-CO, respectively ( Figure 4 and Table 2 ). Others have used this shift in absorbance, 38, 55 or a shift in the Raman heme spectrum upon addition of YC-1 or BAY 41-2272, [35] [36] [37] 56, 58 to argue that YC-1 family compounds bind to the heme domain. However, the high concentrations of YC-1 used in those studies (generally 200 μM) raise the concern that the spectral changes may have arisen from nonspecific binding. Here, we demonstrate that only nanomolar quantities of YC-1 are required for inducing the shift in the Ms sGC-NT-CO Soret absorption band, consistent with a specific binding event.
YC-1 readily enhances CO binding in Ms sGC-NT proteins (Table 1 and ref 33) , which lack the cyclase domain, but does not stimulate the isolated cyclase domains. 59 YC-1 also readily enhances binding of CO to Ms sGC-NT21 (Table 1 and ref  43) , which does not contain the α 1 H-NOX domain, ruling out the possibility of the α 1 H-NOX domain containing the binding site. A similar conclusion was reached for truncated versions of mammalian sGC proteins. 48−50 These data, taken together with our SPR and spectral data, provide a compelling argument for heme domain binding of YC-1 family compounds.
Results using the bovine protein are qualitatively the same as those for the Manduca protein but differ in the dissociation constants for CO binding. Bt sGC β 1 (1−197) binds CO ∼8-fold less tightly than Ms sGC β 1 (1−380) (Table 1) , while binding by Bt sGC β 1 (1−359) is weaker yet, ∼9-fold weaker than binding by Bt sGC β 1 (1−197) . Neither bovine protein displays a significant response to YC-1. The difference in CO affinity between Bt sGC β 1 (1−197) and Bt sGC β 1 (1−359) may result from stabilization of the lower-affinity form of the H-NOX domain upon homodimer formation in the larger protein or from interactions between the H-NOX and PAS domains.
YC-1 Binding Relieves Inhibition of the β 1 Heme Domain by the α 1 H-NOX and PAS Domains. Perhaps our most unexpected finding is that the affinity of CO for heme in the β 1 H-NOX domain is as high in the absence of other domains as it is in the presence of YC-1 (Table 1) . We showed previously that YC-1 binding leads to tighter CO binding in Ms sGC-NT constructs 33 and that binding leads to the development of a geminate recombination phase upon CO photolysis. 41 Negrerie and co-workers recently showed that the isolated human H-NOX domain [β 1 (1−190) ] also displays a geminate rebinding phase whereas the full-length protein does not. 60 This tighter binding and trapped CO correlate with increased cyclase activity for full-length sGC proteins. 25, 61 We now show that both the α 1 PAS and α 1 H-NOX domains impair CO binding ( Table 1) . Removal of the α 1 H-NOX domain enhances CO binding by 24-fold, and complete removal of the α 1 chain enhances CO binding by 265-fold ( Table 1) . Binding of CO to Ms sGC β 1 (1−380) in the absence of YC-1 is as tight (K d CO = 0.20 μM) as binding to any of the Ms sGC-NT proteins in the presence of YC-1. Cooperativity in binding of CO to any of the constructs missing the α 1 chain is now largely absent (K int ∼ 1), and YC-1 binding does not appreciably enhance CO binding (Table 1 ). In addition to tightly binding CO, Ms sGC β 1 (1−380) presumably also binds tightly to YC-1 and BAY 41-2272.
The situation with NO binding is similar to that for CO but apparently differs with respect to cooperativity. Unlike CO binding, NO binding leads to proximal histidine cleavage and a five-coordinate Fe−NO complex. NO release is multiphasic. We previously showed that binding of YC-1 to Ms sGC-NT-NO eliminated the faster of two NO release rates, yielding a protein with higher NO affinity, much like what occurs with CO. 33 However, unlike with CO, the data in Table 2 indicate that binding of NO enhances binding of PF-25 to Ms sGC β 1 (1−380) by ∼10-fold, indicating that cooperativity occurs for NO with this protein but not for CO. The reason for this difference is unclear but may have to do with the difference in heme domain conformation for the five-coordinate and sixcoordinate Ms sGC proteins.
We recently determined the crystal structure of Ms sGC α 1 PAS 17 and a molecular model for domain packing based on homology modeling, chemical cross-linking, and SAXS analysis. 43 These data indicate a direct contact between one face of helix Fα in Ms sGC α 1 PAS, involving residues Glu 340 and Lys 343, and the subdomain containing proximal His 105 that is proposed to be involved in signal transduction 62−64 ( Figure 6 ). This contact in the intact protein may serve to stabilize the H-NOX domain in a low-affinity conformation. A pocket in this subdomain identified in our homology model may be the YC-1 binding site and provide a means for counteracting the effects of α 1 PAS inhibition. Our cross-linking data also indicate direct contact between the α 1 and β 1 H-NOX domains ( Figure 6 ). This contact is farther from the heme and may serve to enhance the α 1 PAS−β 1 H-NOX interaction.
Binding Binding of YC-1 family compounds to Ms sGC-NT-CO complexes is 10−200-fold tighter than that to Ms sGC-NT ( Figure 4 and Tables 2 and 3 ). BAY 41-2272 binds particularly tightly to the CO complexes, displaying dissociation constants of 30−90 nM. Thus, the enhanced stimulation of sGC by BAY 41-2272 as compared to that with other YC-1 family compounds appears to be due to especially tight binding to the active conformation.
Binding of PF-25 to the Ms sGC-NT21-NO complex, examined using SPR, was ∼2-fold weaker than binding to the Ms sGC β 1 (1−380)-NO complex, consistent with the unliganded and CO-bound binding studies (Table 2) , and consistent with a model in which the α 1 PAS domain inhibits binding of CO, NO, or YC-1 family compounds. Interestingly, binding of PF-25 to the Ms sGC-NT21-NO complex is 3−12-fold weaker than binding to the Ms sGC-NT21-CO complex.
The YC-1 dissociation constants we measure for the unliganded and truncated Ms sGC proteins are similar to those reported for binding and stimulating the full-length protein. Binding to full-length bovine lung sGC was monitored using equilibrium dialysis, yielding a K d of 52 μM when measured in the presence of Mn 2+ , 32 and by the effective concentration needed to achieve 50% maximal stimulation of unliganded bovine sGC, yielding an EC 50 of ∼20 μM. 24 These values compare favorably with those of a stimulator binding to . This agreement between binding affinity for Ms sGC-NT and the concentration needed to stimulate activity in the full-length protein provides confidence that our measurements reflect the functionally important binding events.
A Model for sGC Regulation. The model that emerges from our data is one in which the low-energy state for the heme pocket differs between the isolated β 1 H-NOX domain and heterodimeric sGC (Figure 7 ). In the isolated domain, the heme pocket traps CO and NO, leading to high affinity for these ligands. In heterodimeric sGC, the heme pocket changes conformation such that NO and CO can more readily escape and binding affinity is reduced. Binding of YC-1 family compounds to heterodimeric sGC alters or severs the connection between the heme domain and α 1 subunit, returning the heme domain to its high-affinity conformation. A prediction of this model is that CO or NO binding will induce the high-affinity heme domain conformation, leading to tighter binding by YC-1 family compounds. Linked equilibria were in fact observed: YC-1 family compounds bind 10−200-fold more tightly in the presence of CO or NO than in their absence ( Table 2) .
A second prediction of this model is that the low-affinity H-NOX conformation inhibits cyclase activity, while the highaffinity conformation relieves this inhibition or is stimulatory. In this way, binding of either YC-1 or CO/NO leads to cyclase activation, and binding of both yields full sGC activation. Support for this model comes from studies of sGC mutant β 1 H105C, in which the heme proximal histidine is mutated to cysteine, leading to heme-free sGC and a presumably highaffinity conformation for the H-NOX domain. This protein displays high basal catalytic activity and can still be stimulated by YC-1. 65, 66 Additional support for the model comes from studies of the rat cyclase domain alone and after addition of the H-NOX domain in trans, which leads to inhibition of cyclase activity 67 and protection of cyclase from hydrogen−deuterium exchange. 64 Although inhibition was insensitive to NO, these data support a model in which the H-NOX domain directly binds to and inhibits the cyclase domain. 67 The possibility that ) and homology models for the α 1 and β 1 H-NOX domains. Cross-links between the two domains identified by mass spectrometry are shown, 43 as are the heme and proximal histidine in the β 1 H-NOX domain. This figure was prepared using PyMOL (W. L. DeLano, http://www.pymol.org). Figure 7 . Model for sGC regulation. Shown is a proposed model for allosteric regulation in sGC in which the β 1 H-NOX is in equilibrium between high-and low-affinity conformations. YC-1, NO, CO, and the absence of α 1 chain H-NOX and PAS domains all shift the equilibria toward high affinity, while the α 1 chain H-NOX and PAS domains shift the equilibria toward low affinity. The low-affinity conformer is inhibitory toward the cyclase domains, while the high-affinity conformer is noninhibitory or possibly stimulatory.
the high-affinity heme domain conformation may in fact stimulate cyclase activity rather than simply remove an inhibitory contact is suggested by experiments with sGC lacking both H-NOX domains, which displays only basal catalytic activity. 57 Interestingly, this protein is also insensitive to BAY 41−2272.
A third prediction of this model is that linked equilibria should exist between nucleotide binding to the cyclase domain and ligand binding to the heme domain. The fact that such a link exists has been previously described. 68−70 In the presence of nucleotide, NO release is slowed, 69 full stimulation by NO enhanced, 68 and desensitization delayed. 70 How the β 1 H-NOX domain switches from low to high CO and NO affinity is unknown. One recently proposed possibility is that the proximal heme pocket is strained in the low-affinity form, leading to heme distortion and inherently poor CO and NO binding affinity. Upon bond breakage, CO and NO escape rather than re-bind to heme. 38, 60, 71, 72 In the high-affinity state, proximal strain is relieved by movement of the proximal histidine and heme iron into the plane of the porphyrin ring, yielding greater CO or NO affinity and a higher capture rate. 72 This model is reminiscent of the "relaxed" and "tense" states described for hemoglobin.
A second possibility is for the heme domain to adopt "open" and "closed" conformations, in which the closed conformation hinders the escape of CO or NO and favors capture by heme. This is the strategy employed by Rhodnius prolixus nitrophorin 4, an NO transport protein. In nitrophorin 4, two loops collapse into the heme pocket at low pH, generating a closed conformation, an increased level of geminate recombination, and a higher affinity for NO. 73−75 Distinguishing between these models awaits determination of high-resolution structures. 
